tumor promoter in two-stage initiation-promotion models and induces cell proliferation and development of enzymealtered hepatic foci. It is believed that increased cell proliferation is a necessary step in carcinogenesis. Therefore, the analysis of the effect of TCDD on cell proliferation in rat liver may aid in the understanding of the mechanism of hepatocarcinogenesis induced by TCDD. The aim of this study was to investigate the time course and reversibility of cell proliferation in non-initiated and diethylnitrosamineinitiated female rats exposed biweekly to a daily averaged dose of 125 ng TCDD/kg/day for up to 60 weeks. In addition we evaluated the suitability of different dose metrics for the evaluation of TCDD-induced changes in cell proliferation and CYP1A1 enzyme induction. Cell proliferation was measured as the incorporation of 5-bromo-2Ј-deoxyuridine (BrdU) into hepatocytes undergoing replicative DNA synthesis. Mean BrdU labeling indices in TCDD-treated animals were not increased over controls after 14 weeks exposure, but were increased 8-and 2-fold after 30 and 60 weeks' treatment respectively, despite similar liver levels of TCDD at all these times (23-30 p.p.b.). In comparison, CYP1A1 activity, as measured by ethoxyresorufin deethylase activity, was significantly induced at all times points analyzed. Sixteen weeks following cessation of TCDD treatment, labeling indices were still significantly elevated over controls, but after 30 weeks of withdrawal, labeling indices were no different from controls, indicating that TCDD-induced changes in cell proliferation were reversible. Dosimetric analysis indicated that rat liver tissue burden was suitable for prediction of CYP1A1 expression but not cell proliferation and that the area under the curve was unsuitable for prediction of both TCDD-induced changes in CYP1A1 expression and cell proliferation.
Introduction
In rodent bioassays, 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD*, dioxin) is a multi-site, multi-species carcinogen in both sexes (1) and potent tumor promoter in liver and skin (2) (3) (4) (5) (6) . The mechanism of action of TCDD and structurally related compounds involves initial binding to the aryl hydrocarbon receptor (AHR). The AHR is a ubiquitous intracellular protein that is found in cells of vertebrates, including rodents and humans, which acts as a signal transducer and activator of gene transcription (7, 8) . Binding of TCDD to and activation of the AHR results in a wide spectrum of biological responses, including altered gene expression [e.g. cytochrome P450 1A1 (CYP1A1) induction], altered metabolism, altered cell growth and differentiation and disruption of steroid hormone and growth factor signal transduction pathways (9, 10) . Consideration of several lines of evidence, including observations of increases in cancer mortality in humans exposed to TCDD and dioxin-like compounds (11) (12) (13) , the carcinogenicity of TCDD in rodents (1) and the conservation of mechanism of action of TCDD through the AHR (8) , has led to the recent classification of TCDD as a known human carcinogen (13) .
Chronic exposure to TCDD in rodent two-stage initiationpromotion models results in a dose-dependent increase in altered hepatic foci development (3, 4) and increases in cell proliferation (14) , as measured by incorporation of 5-bromo-2Ј-deoxyuridine (BrdU) into hepatocytes undergoing replicative DNA synthesis. TCDD-induced changes in cell proliferation is a highly variable response, with some highly responsive animals exhibiting a high degree of cell labeling (14) . Many rodent carcinogens have been shown to result in increased cell proliferation (15) (16) (17) . Chemically induced cell proliferation may aid in the selective growth of preneoplastic cells and the fixation of DNA damage into mutations. In TCDD-treated ovariectomized rats, a lack of induction of cell proliferation by TCDD correlated with a lower incidence of liver tumors in these animals, compared with sham-operated TCDD-treated controls (3) . Therefore, an understanding of the effect of TCDD on cell proliferation may aid in the understanding of the mechanism of carcinogenesis of TCDD.
The environmental persistence, lipophilicity and subsequent bio-accumulation of dioxin-like compounds results in chronic exposure of humans (18) . Furthermore, different populations are exposed at different doses, at different ages and for different lengths of time. Therefore, it is important to understand the effect of not only magnitude of exposure, but also age at exposure and duration of exposure on the mechanism of carcinogenesis of TCDD. In a previous pilot study, increases in foci development but not cell proliferation were reversible upon cessation of exposure to TCDD (19) . The limited group design in the pilot study and high inter-individual variability in the observed BrdU labeling index prompted a further analysis of the effect of discontinuous treatment with TCDD on changes in cell proliferation in the female Sprague-Dawley rat liver.
In this paper we show that in contrast to CYP1A1 enzyme induction, TCDD-induced changes in cell proliferation in rat liver are dependent upon the timing and duration of TCDD exposure. We also demonstrate that TCDD-induced changes Fig. 1 . Experimental design used in this study. Female Sprague-Dawley rats were initiated with either 175 mg DEN/kg body wt or saline at 10 weeks of age. Starting 2 or 18 weeks after initiation, animals were treated biweekly with TCDD (T) at a daily averaged dose of 125 ng TCDD/kg/day for up to 60 weeks (solid bars) or received corn oil (C) alone (solid lines). Animal necropsies were done 1 week after the last treatment.
in cell proliferation are reversible and that the kinetics of reversibility for various TCDD-inducible end-points are dependent on the duration of withdrawal of TCDD treatment. We also demonstrate that tissue burden and area under the curve (AUC) are unsuitable as dose metrics for TCDD-induced changes in cell proliferation.
Materials and methods

Animal handling and treatment
All procedures and experiments with animals in this study were approved by the Animal Care and Use Committee at the NIEHS. Female Sprague-Dawley rats were randomly divided into 21 groups containing 5-15 animals/group. Animals were housed three to a cage under conditions of controled temperature (70 Ϯ 0.5°F), humidity (50 Ϯ 5%) and lighting (12 h light/12 h dark) and received food and water ad libitum. Animals were either initiated with 175 mg diethylnitrosamine (DEN)/ml/kg body wt at 10 weeks of age or received saline alone. TCDD stock solutions in corn oil were prepared by Radian (Morrisville, NC). Concentration and purity were confirmed by GC/MS analysis. TCDD treatment was by oral gavage, biweekly, at a dose of 1750 ng/kg body wt, to give a daily averaged dose of 125 ng TCDD/kg/day. Control animals received corn oil alone. Seven days prior to necropsy, osmotic minipumps (10 µl/h delivery rate; Alzet model 2ML1; Alzet, Palo Alto, CA) containing 30 mg/ml BrdU in distilled water were implanted s.c. A period of seven days was chosen to allow for sufficient cell labeling and to allow for comparison of labeling indices with previous studies from this laboratory (14, 19) . Seven day pumps had sufficient residual volume to pump for 10 days to ensure that the BrdU reservoir was not depleted over the labeling period. Animals were killed by asphyxiation with CO 2 1 week after the last treatment with either corn oil or TCDD.
The treatment groups used in this study are shown in Figure 1 . The study consisted of four basic study arms. Continuous group. Beginning 2 weeks after initiation, animals were dosed biweekly with TCDD for up to 60 weeks. Animal necropsies were performed 15, 31 and 61 weeks after start of treatment. Control animals received corn oil alone (C) and necropsies were done at 15 Waiting ϩ withdrawal. For some animals in the waiting group, TCDD treatment was stopped after 30 weeks' TCDD treatment and the animals were subsequently dosed with corn oil (group 0-16-30-16). Necropsies were done 17 weeks after the last treatment with TCDD.
Biochemical and histochemical analyses
Representative sections of liver were fixed overnight in freshly prepared 4% paraformaldehyde and embedded in paraffin, together with a section of small intestine as a positive control for analysis of cell proliferation. Other sections of liver were removed, minced and aliquots frozen immediately in liquid nitrogen. Measurement of levels of TCDD in the frozen liver tissue taken at necropsy was performed by Triangle Laboratories (Durham, NC) by GC/MS as described (3) . TCDD levels are shown in the text as p.p.t. relative to wet tissue weight and represent the actual level of TCDD in the tissue taken at necropsy, which for all groups was 1 week after the last dosing with either TCDD or corn oil. Previous studies have shown that the detection of TCDD in liver of untreated animals is dependent upon the limit of detection of the assay and the sample size used. In all cases where the assay was sufficiently sensitive, TCDD has been detected in untreated animals. Therefore, in this study when TCDD could not be detected, a value of half the detection limit was used for statistical analyses. In addition, liver concentrations and total dose (AUC) were predicted using a physiologically based pharmacokinetic model (20) . Cell proliferation was measured by immunohistochemical detection of BrdU incorporation into the nuclei of hepatocytes undergoing replicative DNA synthesis and expressed as the labeling index (LI) (percentage of hepatocytes positively labeled). BrdU staining was carried out by Pathology Associates (Durham, NC) and LIs determined by scoring at least 2000 hepatocytes, in non-focal tissue, in the left lobe in 10 random fields. Scoring for BrdU staining was carried out under avoidance of histological foci by comparison of the BrdU stained slide with a serial section stained with hematoxylin and eosin. LIs in the foci were not determined. Systemic delivery of BrdU was confirmed by examining a section of duodenum taken from each animal at necropsy. Homogeneity of labeling was evaluated by perusing liver tissue sections for nuclear labeling and found to be similar among lobes. Lobular distribution of labeling was examined and found to be panlobular without any acinar-specific pattern. CYP1A1 activity was measured as ethoxyresorufin deethylase (EROD) activity as previously described (21) .
Statistical analyses
Tabulated data are represented as the means Ϯ SD. Because the data in several groups appeared to be highly skewed and not normally distributed, nonparametric methods were used to assess overall group differences (KruskalWallis tests). Pairwise comparisons were carried out by rank order-based Mann-Whitney U tests. For comparisons between TCDD-treated and control groups, C30 served as the control group for group TCCD-treated T0-16-14, C30-16 served as the control group for group T0-16-30 and C60 served as the control group for group T30-30 and T16-30-16 ( Figure 1 ).
Results
Time course of changes in TCDD content and CYP1A1 activity and cell proliferation
Biweekly treatment with a daily averaged dose of 125 ng TCDD/kg/day for 14 weeks resulted in an~1000-fold elevation in TCDD content in the liver (22 and 25 p.p.b. in non-initiated and DEN-initiated animals respectively) ( Table I) . Expression of CYP1A1, as measured by increase in EROD activity, was induced Ͼ23-fold by TCDD (Table II) . However, no increase in BrdU labeling indices were observed after 14 weeks' TCDD treatment (T14) relative to control animals (C14) (Table III and Figure 2) . Surprisingly, BrdU LIs were significantly reduced compared with controls in non-initiated animals treated for 15 weeks (Mann-Whitney U test, P Ͻ 0.05).
After 30 weeks' TCDD exposure, TCDD levels were similar to those treated for 14 weeks (22 and 23 p.p.b. in non-initiated and DEN-initiated animals respectively) ( Table I) . TCDD concentrations in the liver of the groups treated with 125 ng TCDD/kg/day for 15 and 30 weeks, as predicted by a mathematical dose-response model of Kohn et al. (20) , werẽ 50% higher than those observed in this study (Table I) . CYP1A1 induction in animals treated for 30 weeks was induced by TCDD Ͼ12-fold compared with control animals (Table II) . In contrast to the observations made after 14 weeks' TCDD exposure, BrdU LIs in DEN-initiated animals treated with TCDD for 30 weeks were now significantly elevated compared with age-matched animals receiving corn oil alone ( Figure 2 ) (Mann-Whitney U test, P Ͻ 0.01). LIs in noninitiated animals treated with TCDD for 30 weeks were also elevated but were not significantly different from controls.
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Mean levels of TCDD in the liver after 60 weeks' exposure were higher than those observed at previous time points (Table I ). In addition, TCDD concentrations in the liver after 60 weeks' exposure were similar to those predicted by the pharmacokinetic model (Table I) . However, the pharmacokinetic model (20) predicted a decrease in liver TCDD with continuous exposure, which was not observed in vivo. This is most likely due to the incorporation of a parameter into the model that predicts loss of TCDD from lysed cells as a result of cytotoxicity. TCDD-induced levels of CYP1A1 activity were similar to those observed at 14 and 30 weeks of continuous treatment (Table II) . Labeling indices were significantly higher than controls (C60) following TCDD treatment for 60 weeks (T60) in both DEN-initiated (P Ͻ 0.05) and non-initiated animals (P Ͻ 0.01) (Figure 2 ). BrdU LIs in DEN-initiated animals receiving corn oil for 60 weeks were significantly higher than those of age-matched non-initiated control animals ( Figure 2) .
The observation that significant increases in cell proliferation only occurred at 60 weeks in non-initiated TCDD-treated animals ( Figure 2 ) corresponded with the highest predicted AUC (Table I) . However, in DEN-initiated TCDD-treated animals, a significant increase in LI was first observed at a lower predicted AUC after 30 weeks' exposure ( Figure 2) .
Effects of withdrawal of TCDD treatment
The effect of cessation of TCDD treatment on cell proliferation was investigated. Animals were treated with TCDD for 30 weeks, after which animals received corn oil instead of TCDD (withdrawal group). Mean TCDD levels in the livers after 16 weeks' withdrawal (Ͻ0.6 p.p.b.) was Ͼ30-fold lower than those observed in the livers of animals exposed to TCDD for 30 weeks (22-23 p.p.b.) (Table I ). These TCDD levels were still significantly elevated over age-matched controls and were higher than predicted by the dose-response model (Table I) . CYP1A1 expression after 16 weeks withdrawal was lower than in non-initiated and DEN-initiated animals continuously exposed to TCDD for 30 weeks respectively, paralleling the reduction in TCDD in the liver (Table II) . The reduction in CYP1A1 activity did not correspond with the predicted AUC of TCDD, which was higher after 16 weeks' withdrawal than Figure 3 ). In comparison, in a previous oral dose-response study, there was no effect on LIs at this level of TCDD in the liver (0.6 p.p.b.) in animals treated biweekly with TCDD for 30 weeks (14) . However, mean LIs after 16 weeks' withdrawal were lower than those observed after 30 weeks continuous dosing and the inter-individual variability was markedly lower. Analysis of reversibility over time indicated that the rate of reversibility of CYP1A1 induction and cell proliferation were similar in DEN-initiated animals, but not in non-initiated animals (data not shown). After 30 weeks' withdrawal, mean levels of TCDD in the liver were 204-fold (non-initiated) and 337-fold (DENinitiated) lower than in animals treated with TCDD for 30 weeks, but still higher than in control animals (Table I) . CYP1A1 activities after 30 weeks' withdrawal were Ͼ13-fold lower than in animals continuously treated with TCDD for 60 weeks, but were still significantly elevated over levels in agematched controls. This reduction in CYP1A1 activity did not correspond with predicted AUC values, which were equivalent after 16 and 30 weeks' withdrawal (Table I) . LIs in both DEN-initiated and non-initiated animals (T30-30) were not significantly different from age-matched corn oil controls (C60) and were significantly lower than indices in both non-initiated and DEN-initiated animals exposed to TCDD continuously for 60 weeks (T60) respectively (Table II) . The reductions in LI and CYP1A1 activities after 30 weeks' withdrawal were in contrast to the predicted AUC, which were higher than that observed after only 30 weeks' TCDD treatment (Table I) . Effects of a waiting period following initiation Animals were exposed to 125 ng TCDD/kg/day following a waiting period of 18 weeks after initiation with 175 mg DEN/ kg (Figure 4) . The time dependence of TCDD-induced changes in cell proliferation in this study group was similar to that observed in animals that did not have a waiting period after DEN initiation, with induction of cell proliferation only occurring after 30 weeks' and not 14 weeks' TCDD treatment (Figure 2 ). LIs in animals after 16 weeks' withdrawal after TCDD exposure (T0-16-30-16) were lower than in age-matched animals that had been exposed to TCDD continuously for 60 weeks (T60) and was not significantly different from agematched controls that had received corn oil alone for 60 weeks (C60) ( Table III) . This rate of reversibility of TCDD-induced changes in cell proliferation was lower compared with that observed in animals that had not had a waiting period after initiation (data not shown). The difference between these two groups was not due to differences in TCDD liver burdens. Indeed, levels of TCDD in the livers of animals in the waiting group after 16 weeks' withdrawal (0.9 p.p.b.) were higher than those in the animals that did not have a waiting period (0.6 p.p.b.) (Figure 1) . It is not known whether this finding is a statistical observation or represents a biological effect of the waiting period on the kinetics of reversibility.
Cell proliferation and liver TCDD dosimetry
We determined the relationship between BrdU LIs and liver TCDD levels in both DEN-initiated and non-initiated rats in the groups used in this study ( Figure 5 ). In non-initiated animals, elevated LIs (Ͼ5%) were observed only at high liver levels of TCDD (Ͼ10 000 p.p.t.). In some animals there was no elevation in LIs, despite levels of TCDD Ͼ10 000 p.p.t. and these corresponded to those animals that had received TCDD for 15 and 30 weeks.
In DEN-initiated animals there was also no clear correlation between liver TCDD levels and LIs ( Figure 5 ). Elevated LIs were observed at liver TCDD levels Ͻ1000 p.p.t.; these values corresponded to animals in the T30-16 group. Similarly, at high TCDD levels Ͼ10 000 p.p.t., LIs in a large number of animals were no greater than that observed in control animals that had liver levels Ͻ100 p.p.t. A number of these animals had only been treated with TCDD for 14 weeks, a time point at which no significant elevation in LIs was observed (Figure 2) . However, many of these values corresponded to animals that had been treated for 30 weeks or more, indicating a high degree of inter-individual variability in response even at high tissue burdens of TCDD.
Effects on liver weight
Relative liver weights (g/100 g body wt) were significantly increased by TCDD treatment in both non-initiated and DENinitiated animals (P Ͻ 0.01) (Table IV) . After 60 weeks' TCDD treatment, relative liver weights in DEN-initiated animals were almost 2-fold higher than in DEN-initiated control animals. Similar observations were seen in animals that had a waiting period after DEN initiation. Relative liver weights in animals treated for 30 weeks followed by corn oil treatment (T30-16) were not significantly elevated over those seen in both DENinitiated and non-initiated age-matched controls. Liver weights in animals treated for 30 weeks followed by corn oil treatment for 30 weeks (T30-30) were not significantly different from age-matched controls (C60) in both non-initiated and DENinitiated groups and were significantly lower than in animals treated with TCDD for 60 weeks. Indeed, levels in noninitiated animals (T30-30) were significantly lower than in age-matched controls that received corn oil alone. These data indicate that TCDD-induced changes in relative liver weights were reversible following cessation of TCDD.
Discussion
A controversial issue in human risk assessment for exposure to dioxin-like compounds is the relationship between exposure and response for both simple responses, such as changes in gene expression, and more complex responses, such as changes b Animals were initiated with a single dose of 175 mg DEN/kg body wt or saline alone at 10 weeks of age. c Animals were treated biweekly with TCDD at a daily averaged dose of 125 ng/kg/day or received corn oil alone. d Significantly different from age-matched controls using a Mann-Whitney U test (P Ͻ 0.05). e Significantly different from age-matched controls using a Mann-Whitney U test (P Ͻ 0.01). f Significantly different from 60 week TCDD-treated DEN-initiated animals, using a Mann-Whitney U test (P Ͻ 0.01).
in cell proliferation and tumor promotion. The aim of this present study was to investigate the time course and reversibility of changes in cell proliferation in the liver of female rats chronically exposed to TCDD and to compare those changes with those in CYP1A1 enzyme induction. In this study it was observed that changes in cell proliferation after high doses were dependent upon the duration of TCDD exposure and that TCDD-induced changes in cell proliferation were reversible after cessation of treatment with TCDD. Previous studies have shown that chronic exposure of female Sprague-Dawley rats to TCDD results in a dose-dependent elevation in hepatic BrdU LIs (14) . TCDD-induced increases in cell proliferation are highly variable (14, 19) and are dependent upon the presence of ovarian hormones (3) . In this study, time course analysis showed that increases in cell proliferation in non-focal tissue were only observed after 30 weeks' or more exposure to TCDD and were not observed after only 14 weeks' exposure. LLs observed in this study using an averaged daily dose of 125 ng/kg/day were similar to those observed in the highest dose used in the dose-response study of Maronpot et al. (14) . Furthermore, in a chronic 2 year bioassay a dose of 100 ng/kg/day resulted in significant elevation of rat liver tumors in female but not male rats.
The absence of a TCDD-induced increase in cell proliferation after 14 weeks' exposure, despite similar tissue concentrations of TCDD, was consistent with other studies showing no significant effect on hepatocyte LIs in animals treated biweekly for up to 17 weeks with an average dose of 100 ng/kg/day (35-40 p.p.b. TCDD in the liver) (22, 23) . Reduced LIs in rat liver have been previously observed in a 2 week acute study (24) and TCDD inhibits liver cell proliferation induced by 2/3 partial hepatectomy (25) . Furthermore, TCDD has been shown to be mito-inhibitory in vitro (26) . Reductions in cell proliferation have also been observed at low doses of TCDD (14) . In this current study there was a small, but statistically significant, reduction in cell proliferation in non-initiated animals after 14 weeks' exposure, suggesting a possible mitoinhibitory effect of TCDD in vivo. However, reductions in cell proliferation at this time point were transitory and continued exposure to 125 ng TCDD/kg/day for up to 60 weeks led to a significant elevation in cell proliferation in apparently normal hepatocytes. The observations in this paper are consistent with the negative selection hypothesis of tumor promotion of Andersen et al., which proposes that TCDD exposure may result in the establishment of an environment in the liver whereby some hepatocyte populations are mito-inhibited (27, 28) . Those altered hepatocyte sub-populations that escape mito-inhibition could potentially gain a growth advantage and could therefore develop into tumors.
It was also observed that TCDD-induced changes in cell proliferation were reversible after cessation of TCDD treatment. Cessation of TCDD treatment led to a reduction in liver TCDD concentration and this was correlated with a reduction in induction of CYP1A1 enzyme activity. It is noteworthy that the time taken for the reversal of the effects of TCDD on cell proliferation was similar to that observed for TCDD-induced increases in cell proliferation, in both cases between 14 and 30 weeks. The reversibility of TCDD-induced changes in cell proliferation are in contrast to a previous pilot study (19) . The reason for this discrepancy is likely due to the high interindividual variation in LIs observed in TCDD-treated rats, combined with the absence of an age-matched DEN-initiated control group in the pilot study design. The reversibility of TCDD-induced changes in cell proliferation correlates with observations that cessation of treatment leads to a reduction in the number of altered hepatic foci in the liver. This has been observed in both this present (29) and in other studies (2, 19) . However, the observations that after withdrawal, foci volume and the fraction of the liver occupied by foci increase (2, 19, 29) suggest that TCDD treatment may select for a population of foci whose growth becomes independent of TCDD treatment at later time points. Changes in cell proliferation may be a necessary step in the early stages of tumor promotion but not sufficient for tumor development. Furthermore, the measurement of cell proliferation may not be a good marker for carcinogenesis at later time points, since it may not include already fixed changes in certain hepatocyte subpopulations.
The mechanism of TCDD-induced changes in cell proliferation in vivo is unknown. The effects of TCDD on cell proliferation may be the result of an effect on pathways that are involved in the normal growth responses. TCDD modulates a variety of peptide growth factor (30-32) (e.g. epidermal growth factor) and steroid hormone (e.g. estrogen receptor) signal transduction pathways (33) (34) (35) (36) . TCDD inhibits gap junction intercellular communication and this may result in an altered growth response (37) . The observation that TCDDinduced increases in cell proliferation are observed after Ͼ14 weeks' treatment, regardless of the age of the animal, indicates that time, in addition to dose, is an important factor in the mechanism. Mathematical models of foci formation in TCDDtreated rats indicate that TCDD may increase the mutation (birth) rate of preneoplastic cells (38, 39) . This may lead to the development of different populations of hepatocytes with differential sensitivity to TCDD, and this may be a contributing factor in the time dependence and variability in effects of TCDD on cell proliferation.
TCDD induction of cell proliferation is observed in both non-initiated and DEN-initiated animals. Given that induction of cell proliferation by TCDD is measured in apparently normal hepatocytes, it is likely that there will be similarities in the mechanism in both non-initiated and DEN-initiated animals. It is unlikely that the observed increases in cell proliferation are due to regenerative cell proliferation following DEN-induced necrosis, since there is no significant difference between corn oil-treated animals initiated with a necrogenic dose of DEN and non-initiated animals. It is possible that the increases in cell proliferation is in response to increased necrosis after TCDD treatment, since TCDD treatment for 30 weeks at 125 ng/kg/day results in increased cytotoxicity, as determined by increased serum liver enzymes (14) . TCDDinduced LIs are higher in DEN-initiated animals, which have a higher focal burden (14) , suggesting that the mechanism may involve an interaction between focal and non-focal tissue.
The observation of time dependence in both the induction and reversibility of changes in cell proliferation suggests that the mechanism for this change is more complex than for a simple response, such as induction of CYP1A1 expression, which can be predicted by liver TCDD concentration. Sound human risk assessment for dioxin-like compounds requires an understanding of the relationship between human exposure and response. There are currently several dose metrics that may be used to relate response to TCDD exposure, including tissue burden, body burden, peak dose, area under the curve and peak area under the curve (40, 41 ). An appropriate dose metric is one that is quantitatively related to a given response, regardless of how the exposure was obtained. Tissue concentration of TCDD has been shown to be a good predictor for simple reversible responses, such as TCDD-induced CYP1 induction following both acute and chronic exposure to TCDD (21, 40) . In this study, elevation in tissue concentrations in the liver following chronic exposure to TCDD corresponded with induction of CYP1A1 protein, an observation consistent with a direct effect of TCDD on CYP1A1 expression. However, we observed no increases in cell proliferation after 14 weeks' TCDD exposure, despite the high tissue burdens of TCDD shown to highly induce CYP1A1. At later time points, cell proliferation was elevated, despite tissue burdens similar to those seen after 14 weeks' exposure. Significant elevations in cell proliferation were also observed in groups that had low tissue burdens of TCDD as a result of withdrawal of TCDD treatment. Furthermore, these elevations in cell proliferation were observed at liver TCDD burdens which have previously been shown to have no effect on cell proliferation when achieved via chronic dosing with a lower administered dose (14) .
The data in this paper extend previous observations to show that while tissue burden correlated with a simple reversible response, such as CYP induction, it did not correlate with a more complex, yet reversible, response, such as TCDD-induced changes in cell proliferation. Furthermore, a dose metric such as AUC, which measures total dose over time, did not correspond with either TCDD-induced changes in cell proliferation or changes in CYP1A1 expression. It is likely that for a number of TCDD-induced responses, particularly those that involve integrated signal transduction pathways, such as altered cell/tissue growth and differentiation, the choice of appropriate dose metric will be response specific. These responses may be better related to a dose metric that incorporates not simply the magnitude of exposure, but also duration of exposure to 1434 TCDD together with potential temporal windows of sensitivity for a given response.
